39 results about "Immunoglobulin-binding protein" patented technology

The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.

The present invention relates to the use of an alkali-stable protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.

The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, Staphylococcus aureus Protein A (SpA), as well as methods of using the same.

The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more Ig binding domains with amino acids selected from the group consisting at least of 1I, 11A, 11E, 11I, 35R, 35I, and 42L. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.

The invention relates to a synthetic method used for preparing an adsorbent for clearing a pathogenic antibody by oxidizing periodate, and discloses a method for preparing a protein immunoadsorption material by oxidizing the periodate by taking agarose gel as a carrier. The method comprises the following steps of: preparing aldehyde group-containing agarose gel by oxidizing the agarose gel by using the periodate; coupling the aldehyde group-containing agarose gel and immunoglobulin binding protein; and blocking a material and reducing or reducing directly without blocking to obtain the immunoadsorption blood purification material. The method has the characteristics of simple process, environmental friendliness, low cost and the like; and simultaneously the product has high specificity, adsorptive property, regenerability and the like, and can be used for clinical immunoadsorption treatment practically.

The present disclosure relates to non-natural binding proteins comprising one or more non-natural immunoglobulin (Ig) binding domains wherein at least one non-natural lg-binding domain comprises the amino acid sequence X1 X2X3XiXsX5X7 XsQQX11AFYX1sX15LX1 sX19PX21 LX23X24X2sQRX28X2gf IQSLKDDPSXio SXi2Xi3Xi4LXi5EAXigKLXs2Xs3Xs4QXs5PX. The disclosure also relates to compositions such as affinity matrices comprising the non-natural Ig-binding proteins of the invention. Use of these Ig-binding proteins or of the compositions for affinity purification of immunoglobulins and to methods of affinity purification.

Provided is an affinity carrier having improved alkali resistance. This immunoglobulin-binding protein contains a mutant polypeptide chain. This affinity carrier includes a solid-phase carrier to which the immunoglobulin-binding protein is bound. The mutant polypeptide chain has an amino acid sequence having at least 85% identity to an amino acid sequence indicated by any of SEQ ID NO: 1-6 and 57-62 and having a predetermined mutation, and has immunoglobulin-binding activity.

The invention relates to the technical field of immunoglobulin separation and purification, in particular to an immunoglobulin binding protein and its application. The immunoglobulin binding protein is spliced ​​from partial fragments of D, C and Z-domain of staphylococcal protein A, and unexpectedly obtains a binding protein with improved alkali resistance, which can then be used for affinity chromatography of immunoglobulins.